AI in Pharmacovigilance: The Future of Drug Safety

The pharmaceutical industry generates millions of patient interactions every year — phone calls to hub services, conversations with specialty pharmacies, reports filed through manufacturer support lines. Buried inside those conversations are safety signals that regulators depend on and patients’ lives may hinge upon. Yet historically, the systems designed to catch those signals have struggled to keep pace. AI in pharmacovigilance is changing that — shifting drug safety programs from reactive, manual processes to proactive, scalable oversight.

According to the World Health Organization, adverse drug reactions are among the leading causes of death and hospitalization worldwide. Despite decades of regulatory investment in safety reporting infrastructure, underreporting remains a persistent problem — with some estimates suggesting that fewer than 10% of adverse events are ever formally captured. For pharmaceutical and life sciences organizations, the challenge isn’t simply compliance. It’s ensuring that the full picture of a drug’s real-world safety profile is visible, actionable, and continuously improving.

What Is Pharmacovigilance and Why Does It Need AI?

Pharmacovigilance (PV) is the science and set of activities relating to the detection, assessment, understanding, and prevention of adverse effects and any other drug-related problems. Governed by global regulatory bodies including the FDA and EMA, PV programs are responsible for monitoring drug safety throughout a product’s entire lifecycle — from clinical trials through post-market surveillance.

In practical terms, that means collecting adverse event (AE) reports, analyzing safety signals across diverse data sources, maintaining compliance with reporting timelines, and continuously evaluating whether a drug’s benefit-risk profile remains acceptable. It’s an enormous responsibility, and traditional pharmacovigilance workflows were not designed for the scale or complexity of today’s data environment.

Patient safety monitoring today involves far more touchpoints than it did even a decade ago. Patients interact with manufacturers through call centers, chatbots, specialty pharmacy programs, patient support hubs, and social media. Each of those interactions can surface clinically relevant safety information — but only if organizations have the infrastructure to listen at scale. That’s where conversation intelligence for pharma and broader AI capabilities are becoming not just useful, but essential.

The Limitations of Traditional Pharmacovigilance

Before AI, pharmacovigilance relied almost entirely on manual processes — and the pain points were significant:

• Manual adverse event intake and data entry: Trained safety associates would review calls, read through transcripts, or sift through written reports to identify potential AEs, then manually enter case details into safety databases. This process is slow, resource-intensive, and highly dependent on individual judgment.

• High volumes of spontaneous safety reports: As drug portfolios expand and patient support programs scale, the volume of inbound communications grows exponentially. PV teams cannot manually review every interaction.

• Inconsistent signal detection across data sources: When data comes from disparate systems — call centers, EHRs, social media, chatbot transcripts — without a unified approach to analysis, safety signals can be missed or detected inconsistently.

• Duplicate reporting and data quality issues: Multiple reports about the same event from different sources create redundancy and inflate case counts, diverting attention from genuine new signals.

• Difficulty analyzing unstructured data: Call center transcripts, electronic health records, and social media posts don’t fit neatly into structured databases. Without tools capable of processing natural language, organizations simply cannot extract value from these sources.

These aren’t just operational headaches — they represent genuine patient safety risk. When capacity constraints limit review to a sample of interactions, real adverse events go undetected.

How AI Is Transforming Pharmacovigilance

AI is fundamentally reshaping how drug safety programs operate, enabling teams to move from reactive case processing to proactive, continuous surveillance. The transformation is happening across the entire PV lifecycle.

At the core are two complementary technologies: natural language processing (NLP) and machine learning. NLP enables systems to read, interpret, and extract meaning from unstructured text and speech — precisely the kind of data that had previously been inaccessible at scale. Machine learning models can be trained to recognize patterns associated with adverse events, product quality complaints, and special situations, then continuously improve their accuracy over time.

The result is a shift from a world where safety teams reviewed what they could to one where every interaction can be evaluated systematically. This enables proactive drug safety surveillance — identifying signals as they emerge in real-world conversations rather than waiting for formal reports to accumulate.

Adverse event detection, once dependent on human reviewers catching a mention of side effects in a call transcript, can now be automated with high precision. Sentiment analysis in healthcare applications adds another layer of insight, helping teams understand not just what patients are reporting, but how they’re experiencing their treatment — a dimension that may surface signals traditional AE detection would miss.

Core AI Capabilities in Drug Safety Monitoring 

The most impactful AI functions in pharmacovigilance include:

Automated adverse event detection: AI models trained on labeled safety data can identify potential AEs in real time across both structured and unstructured sources, dramatically reducing the manual review burden.

Special situation identification: Beyond standard AEs, AI can surface other reportable scenarios — off-label use, medication exposure during pregnancy, product misuse — that would require significant human expertise to detect at scale.

Signal detection and prioritization: Rather than reviewing every flagged interaction with equal urgency, AI can rank signals by severity and clinical relevance, ensuring that the highest-risk cases receive immediate attention.

Automated case documentation: When a potential safety event is identified, AI can pull relevant details from the source interaction and begin populating safety forms, reducing data entry time and improving consistency.

Continuous model improvement: Supervised AI approaches — where human experts validate AI outputs and provide ongoing feedback — enable models to become more precise over time, reducing false positives that divert team capacity.

For a detailed look at how these capabilities work in practice, visit this link.

The Role of Conversation Intelligence in Pharmacovigilance

Among the most underutilized data sources in drug safety is the one that’s arguably most valuable: the actual conversations patients have with manufacturers, support programs, and specialty pharmacy teams.

When a patient calls a hub service to ask about a medication side effect, or mentions to a specialty pharmacy representative that they’ve stopped their therapy because of nausea, that information contains clinically significant safety data. In traditional PV workflows, capturing that data depends entirely on whether the agent recognized the disclosure, properly documented it, and routed it through the right channels. In high-volume environments with variable agent training, those conditions aren’t consistently met.

Conversation intelligence addresses this gap directly. By applying NLP and machine learning to spoken and written patient interactions, conversation intelligence platforms can analyze 100% of interactions — not just a random sample — to surface safety signals at scale. This isn’t about replacing trained safety reviewers; it’s about ensuring that reviewers are looking at the right interactions, with full context, rather than sorting through noise.

For pharmaceutical manufacturers, this has practical implications across several key touchpoints:

Patient support hubs: Patients enrolled in specialty therapy programs often have complex medication experiences. Hub interactions are rich with spontaneous disclosures about side effects, tolerability challenges, and clinical outcomes — data that belongs in the safety database.

Specialty pharmacy interactions: Patients filling specialty prescriptions frequently call with questions about their therapy that surface unreported adverse events. Systematic analysis of these conversations can capture signals that would otherwise remain invisible.

Manufacturer support lines: Direct-to-manufacturer contact centers receive inbound communications that run the full spectrum — from product questions to serious adverse event disclosures. Monitoring these at scale requires AI.

Platforms like Authenticx are purpose-built to analyze these interactions at scale. Rather than reviewing a sample, the technology listens to every conversation and automatically flags potential safety events — then routes them to reviewers with the relevant transcript context, a complete audit trail, and pre-populated safety form data ready for validation.

Critically, this approach supports patient experience analytics that go beyond simple event detection. Understanding how patients are experiencing their therapy — the language they use to describe symptoms, the questions they’re asking, the concerns prompting them to call — gives safety teams richer context for signal interpretation and benefit-risk assessment.

One major global pharmaceutical manufacturer found that when they applied supervised AI to their chatbot and voicebot interactions, they achieved approximately 90% reduction in manual adverse event and product complaint review immediately, with 100% elimination following validated model performance. The system achieved 99% accuracy across more than 372,000 interactions — and earned favorable findings during a regulatory audit for the rigor of the review framework. That outcome illustrates what’s possible when conversation intelligence is integrated into pharmacovigilance workflows with appropriate human oversight.

Learn more about how Authenticx’s Safety & Compliance product supports pharmacovigilance teams across detection, review, and reporting workflows.

Regulatory Considerations for AI in Pharmacovigilance

Regulatory bodies are actively engaging with AI in drug safety, and the guidance landscape is evolving quickly.

In January 2025, the FDA released draft guidance on the use of AI to support regulatory decision-making, with explicit applicability to pharmacovigilance applications. The guidance emphasizes transparency, documentation of AI model development and validation, and the importance of human oversight in AI-assisted safety workflows.

Then in January 2026, the FDA and EMA jointly published Guiding Principles of Good AI Practice in Drug Development — a significant step toward international alignment on AI governance in the pharmaceutical space. The joint guidance addresses data quality, model validation, transparency, and the expectation that AI tools used in regulatory contexts will be subject to ongoing performance monitoring.

For PV teams, these developments have two practical implications. First, AI adoption in pharmacovigilance isn’t just permissible — regulators are actively developing frameworks to support it. Second, the expectation of documentation, validation, and human oversight means that “black box” AI approaches are unlikely to withstand regulatory scrutiny. The AI solutions that will hold up are those built with explainability, audit trails, and continuous human review as foundational design principles.

Organizations investing in AI for pharmacovigilance should be tracking regulatory guidance updates from the FDA’s CDER and the EMA’s guidance on AI in medicines development, and ensuring their AI partners can provide the validation documentation regulators will expect.

Challenges to Implementing AI in Pharmacovigilance

Despite the clear potential, implementing AI in pharmacovigilance is not without challenges. A balanced view of the barriers helps organizations plan for successful adoption rather than being caught off guard.

Privacy and data governance: Patient safety data is among the most sensitive information pharmaceutical organizations handle. Any AI system that processes patient conversations or health records must be built on a foundation of HIPAA compliance, GDPR where applicable, and robust data security practices. This includes automated PII redaction, role-based access controls, and complete audit trails for all data handling. Organizations should evaluate AI vendors not just on their capabilities, but on the rigor of their privacy and security infrastructure.

Integration with legacy systems: Most pharmaceutical manufacturers have established pharmacovigilance platforms — Argus, ARISg, Veeva Vault Safety, and others — that have been built over years. Integrating AI-powered detection tools with these existing systems requires careful planning, open API access, and vendor support for data interoperability. Without clean integration, AI outputs can create additional manual work rather than reducing it.

Workforce readiness: AI changes the nature of pharmacovigilance work rather than eliminating it. Safety associates who previously reviewed interactions manually will shift to validating AI outputs, investigating flagged signals, and providing the feedback that improves model performance over time. This requires upskilling and change management — ensuring that teams understand how to work with AI outputs, when to trust them, and when to escalate edge cases.

Model validation and regulatory acceptance: As noted above, regulators expect AI tools used in safety contexts to be validated and documented. This means AI adoption in PV isn’t a simple plug-and-play decision — it requires investment in validation workflows, model performance monitoring, and documentation practices that will satisfy regulatory review.

Throughout all of these challenges, the most important principle remains constant: AI in pharmacovigilance is a decision support tool. It expands the scope of what safety teams can monitor, improves the consistency of detection, and reduces the manual burden of data entry and case triage. But the clinical and regulatory judgment that determines how to act on safety signals remains — and should remain — a human responsibility.

How to Evaluate AI-Powered Pharmacovigilance Software

When assessing AI solutions for pharmacovigilance, the technical capabilities matter — but so do the operational and compliance considerations that will determine whether the solution actually holds up in a regulated environment. Here are the key criteria to evaluate:

NLP accuracy and domain specificity: General-purpose NLP models trained on broad datasets may not perform reliably on pharmaceutical and clinical language. Look for solutions with pharmacovigilance-specific model training, published accuracy metrics across large validated datasets, and a track record of improving precision over time through supervised learning.

Coverage and completeness: AI that reviews a sample of interactions replicates the core limitation of manual review. The most impactful solutions analyze 100% of relevant interactions, ensuring that no adverse event disclosure goes unexamined simply because it occurred in an interaction that wasn’t pulled for review.

Explainability and audit trails: Regulators expect to be able to trace safety decisions back through the data. AI outputs should include specific transcript highlighting that shows exactly where in a conversation a potential safety event was identified, complete case documentation, and workflow logs that demonstrate how cases moved through the review process.

Integration with PV platforms: Evaluate whether the solution integrates natively with your existing safety database. Seamless data transfer reduces manual re-entry errors and supports timely reporting. Authenticx, for example, integrates with Trilogy, Veeva Vault, and other leading PV platforms via open API, with safety form automation that pre-populates case data for reviewer validation.

Human oversight architecture: The most defensible AI implementations are those designed around continuous human review — not autonomous AI making final safety determinations. Look for solutions that build in structured validation workflows, human-in-the-loop feedback mechanisms, and dedicated support for ongoing model refinement.

Compliance infrastructure: HIPAA, GDPR, audit readiness, automated PII redaction — these aren’t optional features for healthcare AI. They’re table stakes. Evaluate vendors on the comprehensiveness of their compliance infrastructure before considering their analytical capabilities.

Authenticx’s Safety & Compliance module was designed specifically to meet these criteria for pharmaceutical and life sciences teams. Combined with Business Insights — which surfaces patterns and trends across the full conversation dataset — and Quality & Coaching, which monitors agent adherence to safety reporting protocols, it provides an integrated foundation for AI-driven pharmacovigilance oversight.

For organizations ready to evaluate what conversation intelligence can do for their drug safety programs, the starting point is understanding what’s currently being missed. Every interaction that goes unreviewed is a potential signal that doesn’t reach the PV team. AI exists to close that gap — not by replacing the safety professionals who interpret and act on signals, but by ensuring those professionals have the complete, consistent, high-quality data they need to do their jobs well.

To explore how building responsible AI in pharmacovigilance works in practice, or to see how Authenticx supports pharmaceutical and life sciences teams, schedule a demo.